NCT04638491View on ClinicalTrials.gov

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

November 4, 2023

Study Completion Date

November 4, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

Lurbinectedin for injection

On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection

Trial Locations (1)

Unknown

Jilin Provincial Tumor Hospital, Changchun

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT04638491 - Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients | Biotech Hunter | Biotech Hunter